Clinically, monoclonal antibodies against the human epidermal growth factor receptor-2 (HER2), e.g., trastuzumab, are commonly used in cancers that overexpress HER2, particularly in breast cancer [172]. This evidence concerns the gene ERBB2 and breast cancer.